SCHEMBL20737258

SCHEMBL20737258

CCOC(=O)C1(N)CCNC1=O

nearest known ligand 0.49

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
POLB P06746 2/20 0.49
OPRM1 P35372 5/20 0.40
ATM Q13315 1/20 0.36
TSHR P16473 1/20 0.35
KDM4E B2RXH2 1/20 0.35
MEN1 O00255 1/20 0.35
MAPT P10636 1/20 0.35
ALOX15 P16050 1/20 0.35
KMT2A Q03164 1/20 0.35
BRD4 O60885 1/20 0.35
SMN1; SMN2 Q16637 2/20 0.34
OPRD1 P41143 3/20 0.33
OPRK1 P41145 3/20 0.33
SLC22A1 O15245 1/20 0.33
SLC6A4 P31645 1/20 0.33
ADRA1A P35348 1/20 0.33
KCNH2 Q12809 1/20 0.33
GAA P10253 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL26670487 0.98 POLB (0.47) POLBOPRM1ATMTSHRKDM4E
SCHEMBL29095734 0.90 POLB (0.46) POLBOPRM1ATMTSHRKDM4E
SCHEMBL21777673 0.81 LMNA (0.33) POLB
SCHEMBL19331557 0.78 POLB (0.50) POLBOPRM1ATMKDM4EMEN1
SCHEMBL16056776 0.78 POLB (0.50) POLBOPRM1ATMKDM4EMEN1
SCHEMBL23388844 0.77 POLB (0.49) POLBOPRM1ATMTSHRKDM4E
SCHEMBL20723267 0.77 POLB (0.49) POLBOPRM1ATMKDM4EMEN1
SCHEMBL10469549 0.76 POLB (0.45) POLBOPRM1ATMTSHRKDM4E
SCHEMBL498176 0.75 POLB (0.46) POLBOPRM1ATMTSHRKDM4E
SCHEMBL1323798 0.75 POLB (0.46) POLBOPRM1ATMTSHRKDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260070896-A1 HETEROCYCLE DERIVATIVES FOR TREATING TRPM3 MEDIATED DISORDERS UNIV LEUVEN KATH (BE) 2026-03-12 US disclosed
US-20250376468-A1 PYRAZOLO[1,5-a]PYRIDINE DERIVATIVES FOR TREATING TRPM3-MEDIATED DISORDERS UNIV LEUVEN KATH (BE) 2025-12-11 US disclosed
US-20250376461-A1 INDAZOLE DERIVATIVES FOR TREATING TRPM3-MEDIATED DISORDERS UNIV LEUVEN KATH (BE) 2025-12-11 US disclosed
US-12404266-B2 Heterocycle derivatives for treating TRPM3 mediated disorders KATHOLIEKE UNIVERSITEIT LEUVEN (BE) 2025-09-02 US disclosed
CN-119998280-A Pyrazolo [1,5-a ] pyridine derivatives for the treatment of TRPM3 mediated disorders 勒芬天主教大学 2025-05-13 CN disclosed
CN-119968362-A Indazole derivatives for the treatment of TRPM3 mediated disorders 勒芬天主教大学 2025-05-09 CN disclosed
EP-4499624-A2 INDAZOLE DERIVATIVES FOR TREATING TRPM3-MEDIATED DISORDERS Katholieke Universiteit Leuven KU Leuven Research & Development (BE) 2025-02-05 EP disclosed
EP-4499636-A2 PYRAZOLO[1,5-A]PYRIDINE DERIVATIVES FOR TREATING TRPM3-MEDIATED DISORDERS Katholieke Universiteit Leuven KU Leuven Research & Development (BE) 2025-02-05 EP disclosed
US-12209081-B2 Heterocycle derivatives for treating TRPM3 mediated disorders KATHOLIEKE UNIVERSITEIT LEUVEN (BE) 2025-01-28 US disclosed
US-20240336602-A1 HETEROCYCLE DERIVATIVES FOR TREATING TRPM3 MEDIATED DISORDERS UNIV LEUVEN KATH (BE) 2024-10-10 US disclosed
US-20240051949-A1 HETEROCYCLE DERIVATIVES FOR TREATING TRPM3 MEDIATED DISORDERS UNIV LEUVEN KATH (BE) 2024-02-15 US disclosed
WO-2023230540-A2 INDAZOLE DERIVATIVES FOR TREATING TRPM3-MEDIATED DISORDERS KATHOLIEKE UNIVERSITEIT LEUVEN (BE) 2023-11-30 WO disclosed
WO-2023230542-A2 PYRAZOLO[1,5-a]PYRIDINE DERIVATIVES FOR TREATING TRPM3-MEDIATED DISORDERS KATHOLIEKE UNIVERSITEIT LEUVEN (BE) 2023-11-30 WO disclosed
EP-4251616-A1 HETEROCYCLE DERIVATIVES FOR TREATING TRPM3 MEDIATED DISORDERS Katholieke Universiteit Leuven (BE) 2023-10-04 EP disclosed
CN-116745283-A Heterocyclic derivatives for the treatment of TRPM3 mediated disorders 勒芬天主教大学 2023-09-12 CN disclosed
WO-2022112352-A1 HETEROCYCLE DERIVATIVES FOR TREATING TRPM3 MEDIATED DISORDERS KATHOLIEKE UNIVERSITEIT LEUVEN (BE) 2022-06-02 WO disclosed
US-11046646-B2 Alkylphenyl compounds BRISTOL-MYERS SQUIBB COMPANY (US) 2021-06-29 US disclosed
US-20210147357-A1 ALKYLPHENYL COMPOUNDS BRISTOL MYERS SQUIBB CO (US) 2021-05-20 US disclosed
WO-2019032632-A1 ALKYLPHENYL COMPOUNDS BRISTOL-MYERS SQUIBB COMPANY (US) 2019-02-14 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12209081-B2 Heterocycle derivatives for treating TRPM3 mediated disorders TRPM4, TRPM6, TRPM2 POLB 4595/4885OPRM1 129/4885ATM 2414/4885
US-20240051949-A1 HETEROCYCLE DERIVATIVES FOR TREATING TRPM3 MEDIATED DISORDERS TRPM4, TRPM6, TRPM2 POLB 4595/4885OPRM1 129/4885ATM 2414/4885
US-20250376468-A1 PYRAZOLO[1,5-a]PYRIDINE DERIVATIVES FOR TREATING TRPM3-MEDIATED DISORDERS TRPV3, TRPM5, TRPM4 POLB 4692/4885OPRM1 298/4885ATM 2126/4885
US-12404266-B2 Heterocycle derivatives for treating TRPM3 mediated disorders TRPM4, TRPM6, TRPM2 POLB 4595/4885OPRM1 129/4885ATM 2414/4885
US-20250376461-A1 INDAZOLE DERIVATIVES FOR TREATING TRPM3-MEDIATED DISORDERS TRPV3, TRPM2, TRPV1 POLB 4721/4885OPRM1 368/4885ATM 2758/4885
US-20210147357-A1 ALKYLPHENYL COMPOUNDS LPAR1, PLA2R1, LPAR3 POLB 3606/4885OPRM1 154/4885ATM 4003/4885
US-20260070896-A1 HETEROCYCLE DERIVATIVES FOR TREATING TRPM3 MEDIATED DISORDERS TRPM6, TRPV3, TRPM2 POLB 3775/4885OPRM1 21/4885ATM 3423/4885
US-20240336602-A1 HETEROCYCLE DERIVATIVES FOR TREATING TRPM3 MEDIATED DISORDERS TRPM4, TRPM6, TRPM2 POLB 4595/4885OPRM1 129/4885ATM 2414/4885
US-11046646-B2 Alkylphenyl compounds S1PR1, S1PR3, S1PR2 POLB 2978/4885OPRM1 231/4885ATM 3057/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.